• ICYMI: PxP2019 update on scope expansion
• Pharmacy practice research winners at PxP2019
• Opioid overdose: age is no safety net
• Updated antiemetic recommendations
• A limited quantity of U.S.-labeled potassium chloride for injection USP concentrate (2mEq/mL) in the 20mL format will be made available for Canadian patients
• Fludarabine supply status and conservation strategies

• Medical Devices Training For Pharmacy Technicians
• Billing 101: Ontario Drug Benefit (ODB) and Third-Party Insurance
• Board Certified Geriatric Pharmacist (BCGP) Preparation Course – Medication Therapy Management for Older Adults

• Ask the Practice Support Network

• Do I really need life insurance?

• DDD Notice No. 19086 posted June 05, 2019 Prescription Forgery Alert
• DDD Notice No. 19087 posted June 06, 2019 Prescription Forgery Alert
• DDD Notice No. 19090 posted June 10, 2019 Health Network System (HNS) and Narcotic Monitoring System (NMS) outages notification to ODP agencies

• Health products manufactured by Konsar Future Nutrition Inc. may pose serious health risks

• OPA announces award winners at PxP2019
• Here's what you're missing at PxP2019!
• Pikangikum evacuation plan

• Women’s Health Conditions
• Managing Your Pharmacy: The Business Essentials
• Pharmacist Health Coaching - Cardiovascular Program Training Course

• Ask the Customer Experience and Administration Team

• Your questions answered on disability insurance

• DDD Notice No. 19082 posted May 31, 2019 Prescription Forgery Alert
• DDD Notice No. 19083 posted May 31, 2019 Identified Forgery Alert – 120 Oxycocet Pills
• DDD Notice No. 19084 posted May 31, 2019 ODB gFOBT PIN to be Discontinued
• DDD Notice No. 19085 posted June 04, 2019 Notice from the Executive Officer: Change to the Health Network System Subscription Agreement for Pharmacy Operators

• Health Product InfoWatch - Safety Updates: Eliquis, Fentora and Keytruda
• Alaris Infusion Sets and Alaris 8100 Pump Module - Health Product Risk Communication - Update – Thursday, May 30th, 2019
• IMPORTANT: Drug Shortage Notification – Multiple Sterile Injectable Products
• Biocell breast implants - Information Update

• Applications for the Universal Influenza Immunization Program (UIIP) are being accepted by the Ministry for 2019/20 influenza season
• Be heard! Last chance to submit comments to Ministry on proposed amendments
• Don't miss these PxP2019 conference sessions on scope of practice, drug shortages and cannabis
• Sports journalist and mental health advocate, Michael Landsberg to open PxP2019 trade show

• Injections and Immunizations Certificate Program - Blended
• Injections and Immunizations Refresher - Blended
• Delivering a Comprehensive Pharmacy-Based Vaccines Program

• Check out our new membership benefit with Manulife Bank!*
• Ask the Customer Experience and Administration Team

• Time to renew your store insurance

• DDD Notice No. 19078 posted May 17, 2019 Prescription Forgery Alert
• DDD Notice No. 19080 posted May 21, 2019 Prescription Forgery Alert

• Important Safety Information on ACTEMRA® (tocilizumab) - Risk of Hepatotoxicity - Hoffmann-La Roche Limited

• Deadline to provide feedback to government on amendments to regulations is May 24, 2019
• OPA and Neighbourhood Pharmacies request your input to long-term care survey
• OPA participates in conversation in long-term care at AdvantAge Convention
• Spring 2019 Issue of Ontario Pharmacist featuring Q&A with conference keynote, André Picard, now available
• Registered yet for conference? Deadline is approaching!

• Medical Devices Training for Pharmacy Technicians
• Personal Branding for Pharmacy Professionals
• Dermatologic Conditions

• Sneak preview to new membership benefit with Manulife Bank!
• Ask the Practice Support Network

• “Must Have Insurance”

• DDD Notice No. 19075 posted May 10, 2019 Prescription Forgery Alert
• DDD Notice No. 19072 posted May 09, 2019 Prescription Forgery Alert

• Provide Your Feedback to Health Quality Ontario - A Quality Standard for Transitions from Hospital to Home
• Drug Shortage Notification – Potassium Chloride for Injection Concentrate USP (2 mEq (mmol) / mL) and Epinephrine Injection USP 0.1 mg / mL (LifeShield Syringes)

• Asthma Management: The Essentials
• Billing 101: Ontario Drug Benefit (ODB) and Third-Party Insurance
• Delivering a Comprehensive Pharmacy-Based Vaccines Program

• Special Conference Promotion - Save $100
• Last Week for Hotel Reservations for PxP2019
• Ask the Customer Experience and Administration Team

• Is your store properly insured?

• DDD Notice No. 19070 posted May 02, 2019 HEALTH NETWORK SYSTEM (HNS) AND NARCOTICS MONITORING SYSTEM (NMS) OUTAGE NOTIFICATION TO ODP AGENCIES
• DDD Notice No. 19071 posted May 02, 2019 Prescription Forgery Alert

• Paclitaxel-Coated Balloons (PCB) and Paclitaxel-Eluting Stents (PES) for the Treatment of Peripheral Arterial Disease (PAD) and the Potential Risk of Long-Term All-Cause Mortality

• Your questions answered on recent proposed pharmacy regulations from Ontario government
• Canadian Foundation for Pharmacy happenings
• Pharmacies surpass doctors’ offices as primary venue for influenza vaccination
• OPA represents at Momentum Loblaw/SDM trade show

• An Update on Direct Oral Anticoagulation
• Essential Cannabis Knowledge for Pharmacists - Certificate Program
• Patient Assessment and Triage

• First 100 will save $100 on conference registration
• Ask the Practice Support Network
• Spring time discounts with Royal Ontario Museum
• Reminder to members in voting districts

• Life Insurance v.s. Mortgage Insurance

• DDD Notice No. 19066 posted April 25, 2019 Notice: Proposals to Establish More Efficient Pharmacy Reimbursement Policies
• DDD Notice No. 19067 posted April 26, 2019 Notice from the Executive Officer
• DDD Notice No. 19068 posted April 30, 2019 Prescription Forgery Alert
• DDD Notice No. 19069 posted April 30, 2019 Prescription Forgery Alert

• Health Canada advises Allergan of its intent to suspend its licences for Biocell breast implants as a precautionary measure
• Health Product InfoWatch
• Alaris Infusion Sets and Alaris 8100 Pump Module - Risk of Over-Infusion

• Announcement to expand scope of practice for pharmacists generates public discussion
• Apply to the Allied Health Professional Development Fund for Compensation of Conference Fees
• OPA Celebrates National Immunization Awareness Week with Record Breaking Year for Flu Shots
• Attention Pharmacies in Timmins, Cornwall, Kapuskasing and Thunder Bay - Potential Increase in NIHB Claims

• An Update On Oral Anticoagulation
• Managing Your Pharmacy: The Business Essentials
• Assessing and Prescribing for Minor Ailments - Full Program

• Meet the Future Leaders in Research at PxP2019
• Ask the Customer Experience and Administration Team

• Ask Us Your Questions on Critical Illness

• ODB Formulary – Edition No. 43, Summary of Changes – April 2019 Summary of Product Changes

• Auro Pharma Inc. voluntarily recalls one lot of Auro-Irbesartan HCT tablets because of nitrosamine impurity
• Intragastric Balloons and Potential Risk of Gastric and Esophageal Perforation, Pancreatitis, and Overinflation

• ICYMI: Provincial Budget Announces Expansion of Scope of Practice for Pharmacists
• Conference Early Bird Deadline is Thursday
• Express Scripts Canada - Pharmacy Provider Manual

• Take-home Naloxone in Community Pharmacies
• Methadone and Buprenorphine/ Naloxone Toolkit
• Opioid Addictions and Substitution Therapy Online Modules

• PxP2019 Conference Social Events
• Ask the Practice Support Network

• Are You Prepared for a Critical Illness?

• DDD Notice No. 19062 posted April 12, 2019 Prescription Forgery Alert

• Drug Shortage / Supply Health System Alert: Zinecard (Dexrazoxane)
• Health Canada approves updates to Mifegymiso prescribing information